Advanced Search

    column
    Tumor Metastasis: Special Issue of Science
    LI Yang-si, WU Yi-long
    2016, 16(3): 129-131. DOI: 10.12019/j.issn.1671-5144.2016.03.001
    Abstract FullText HTML PDF
    CheckMate 032 Trial: Opportunities and Challenges of Immunotherapy for Small Cell Lung Cancer
    LEI Yuan-yuan, WU Si-pei, DONG Zhong-yi
    2016, 16(3): 132-133. DOI: 10.12019/j.issn.1671-5144.2016.03.002
    Abstract FullText HTML PDF
    Adjuvant Therapy in Early-Stage Small Cell Lung Cancer: How to Choose Wisely?
    ZHANG Yi-chen, ZHONG Wen-zhao
    2016, 16(3): 134-135. DOI: 10.12019/j.issn.1671-5144.2016.03.003
    Abstract FullText HTML PDF
    Mechanisms of Acquired Drug Resistance to Anti-PD-1 Therapy: A New Immune Checkpoint TIM3 Activation
    DONG Zhong-yi, ZHONG Wen-zhao
    2016, 16(3): 135-136. DOI: 10.12019/j.issn.1671-5144.2016.03.004
    Abstract FullText HTML PDF
    Go Beyond The Cognition of The Past: 2016 Breast Cancer Endocrine Accurate Treatment
    LIAO Ning
    2016, 16(3): 136-142. DOI: 10.12019/j.issn.1671-5144.2016.03.005
    Abstract FullText HTML PDF
    Analysis of ESR1 Mutation in Circulating Tumor DNA Demonstrates Evolution during Therapy for Advanced Breast Cancer
    Reviewers: YE Chang-sheng, YAO Guang-yu, Literature Co-worker: ZHOU Wen-qi
    2016, 16(3): 143-144. DOI: 10.12019/j.issn.1671-5144.2016.03.006
    Abstract FullText HTML PDF
    The Interpretation of BOLERO-2 Trial: Clinical Application Analysis on Everolimus Plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer
    Reviewer: WANG Xian-ming, Literature Co-worker: XIAO Yu
    2016, 16(3): 145-148. DOI: 10.12019/j.issn.1671-5144.2016.03.007
    Abstract FullText HTML PDF
    PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib （BUP） Plus Fulvestrant （FULV） in Breast Cancer Patient with Aromatase Inhibitors
    Reviewer: WANG Ning-xia, Literature Co-worker: ZHANG Yi-fang
    2016, 16(3): 149-151. DOI: 10.12019/j.issn.1671-5144.2016.03.008
    Abstract FullText HTML PDF
    PALOMA-3 Trial: Fulvestrant Plus Palbociclib Improve Progression-Free Survival of Advanced Breast Cancer Patients with Endocrine Treatment Failure
    Reviewer: WANG Shu-sen, Literature Co-worker: ZHANG Liu-lu
    2016, 16(3): 152-154. DOI: 10.12019/j.issn.1671-5144.2016.03.009
    Abstract FullText HTML PDF
    Relationship between Clinicians’ Professional Stressors and Coping Styles
    ZHANG Bai-fang, YIN Shao-ya, ZHAO Jing-bo
    2016, 16(3): 155-158. DOI: 10.12019/j.issn.1671-5144.2016.03.010
    Abstract FullText HTML PDF
    A Method of Data Extraction and Meta-Analysis for miRNA-122 in The Diagnosis of Chronic Viral Hepatitis from Healthy
    QU Zhen, HU Cui-ping
    2016, 16(3): 159-164. DOI: 10.12019/j.issn.1671-5144.2016.03.011
    Abstract FullText HTML PDF
    Effect of Intraoperative Restrictive Fluid Regimes on Outcome after Intraabdominal Surgery: A Meta-Analysis
    DUAN Jun-cheng, JIA Lei, GE Yao, HU Bin
    2016, 16(3): 165-173. DOI: 10.12019/j.issn.1671-5144.2016.03.012
    Abstract FullText HTML PDF
    Oral Contraceptive May Increase The Risk of Breast Cancer among Chinese Women: A Meta-Analysis
    SHI Bin-hao, XU Ping, SUN Ye-huan
    2016, 16(3): 174-179. DOI: 10.12019/j.issn.1671-5144.2016.03.013
    Abstract FullText HTML PDF
    Bibliometric Analysis and Quality Evaluation of Qualitative Research Published in Chinese Medical Association Journals
    ZHAO Rui, BAI Zheng-gang, ZHANG Jing-yi, LENG Yun-xi
    2016, 16(3): 180-185. DOI: 10.12019/j.issn.1671-5144.2016.03.014
    Abstract FullText HTML PDF
    CrizotinibNeoadjuvant Therapy for ⅢA/N2 Lung Cancer
    ZHONG Wen-zhao, CHEN Ying
    2016, 16(3): 186-192. DOI: 10.12019/j.issn.1671-5144.2016.03.015
    Abstract FullText HTML PDF